IDL Diagnostics AB (publ)
IDLDX.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$132.23M
Close$
Share Statistics
| Market cap | $132.23 Million |
|---|---|
| Enterprise Value | $109.07 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.05 |
| Beta | 0.94 |
| Outstanding Shares | 230,361,066 |
Return
| Return on Equity | 10.25% |
|---|---|
| Return on Assets | 8.68% |
| Return on Invested Capital | 17.42% |
Valuation & Multiples
| P/E Ratio | 5.85 |
|---|---|
| PEG | -6.3 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.85 |
| Enterprise Value to EBIT | 3.96 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$19.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$18.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About IDL Diagnostics AB (publ)
25 employees
CEO: Gustav Sten Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-o...